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Translation controlTranslation control often takes place through the mRNA untranslated regions, involving direct interac-
tions with RNA-binding proteins (RBPs). Internal ribosome entry site elements (IRESs) are cis-acting
RNA regions that promote translation initiation using a cap-independent mechanism. A subset of
positive-strand RNA viruses harbor IRESs as a strategy to ensure efﬁcient viral protein synthesis. IRESs
are organized in modular structural domains with a division of functions. However, viral IRESs vary in
nucleotide sequence, secondary RNA structure, and transacting factor requirements. Therefore,
in-depth studies are needed to understand how distinct types of viral IRESs perform their function. In this
review we describe methods to isolate and identify RNA-binding proteins important for IRES activity, and
to study the impact of RNA structure and RNA–protein interactions on IRES activity.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Viral RNAs have evolved mechanisms to initiate translation dif-
ferent from cellular mRNAs. Most cellular mRNAs initiate protein
synthesis using a mechanism that depends on the recognition of
the m7G(50)ppp(50)N structure (termed cap) located at the 50 end
of mRNAs (reviewed in [1]). In contrast, the picornavirus genomic
RNA initiate translation internally through a cis-acting region des-
ignated internal ribosome entry site (IRES) element, using a
cap-independent mechanism [2,3]. Moreover, IRESs also drive
translation initiation in hepatitis C virus (HCV), pestiviruses,
dicistroviruses, retroviruses, and some plant RNA viruses [4–6].
IRESs differ in primary sequence, RNA structure and trans-act-
ing factors requirement, hence promoting internal initiation
throughout distinct mechanisms. The intergenic region (IGR) of
dicistroviruses can assemble a preinitiation 48S complex in the
absence of any initiation factor [7]. The IGR consists of a
three-pseudoknoted (PKI-III) RNA structure [8] in which PKI mim-
ics a tRNA/mRNA interaction in the decoding center of the 40S
ribosomal subunit [9]. The HCV-like IRESs, also present in pes-
tiviruses and some picornaviruses [10,11], represent the next level
of complexity. These IRESs require eIF3 and the ternary complex
(eIF2-GTP-metRNAi) to assemble 48S initiation complexes in
reconstitution assays [12]. The RNA structure of the HCV IRES is
organized in conformationally ﬂexible domains, designated II, III,and IV. Each domain performs a different function during internal
initiation of translation. Domain III binds the 40S ribosomal sub-
unit and eIF3; domain IV harbors the AUG initiation codon; and
domain II is involved in eIF2-catalyzed GTP hydrolysis and 60S
subunit joining. In addition, domain II contacts the ribosomal pro-
teins RPS5 and RPS25, stabilizing the ribosome in a single confor-
mation leading to translation initiation [13,14]. Concerning the
interaction of viral IRESs with ribosomal proteins, recent evidences
have shown that depletion of RPS25 in mammalian cells affects
HCV and IGR IRES activity, and to a lower extent, picornavirus
IRES function [15].
The highest level of complexity is so far found in picornavirus
IRESs. These elements are diverse in primary sequence and sec-
ondary RNA structure, being classiﬁed into ﬁve different types
[16]. Functionally related picornavirus IRESs harbor a common
RNAstructure core and sequencemotifsmaintainedby evolutionary
conserved covariant substitutions [17]. Assembly of 48S initiation
complexes into IRESs of entero-, cardio-, and aphthovirus requires
eIF4G, eIF4A, eIF1, eIF3 and the ternary complex. In addition, host
proteins designated IRES-transacting factors (ITAFs) contribute to
IRES activity [18,19]. ITAFs are RNA-binding proteins (RBPs) also
involved in splicing, RNA transport, or RNA stability [20],which gen-
erally do not contribute to the canonical cap-dependent translation
initiation mechanism. Cleavage of host factors in
picornavirus-infected cells by viral proteases (L, 2A and 3C) disrupts
cap-dependent protein synthesis, in addition to affect transcription,
nucleo-cytoplasmic transport, and RNA granules composition. This
adverse situation for cellular gene expression, however, does not
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RNAsevade translation inhibitionandhijack the translationmachin-
ery taking advantage of host factor proteolysis products that, in
some cases, activate IRES function [21].
Generally, IRES activity is determined as the expression of
reporter genes from dicistronic or monocistronic reporter RNAs.
In the ﬁrst case, the expression of the second reporter gene is nor-
malized to the protein expressed from the ﬁrst cistron, which mon-
itors cap-dependent translation. In the second case, protein
synthesis driven by the IRESs should be normalized to the expres-
sion from another RNA, transfected in parallel. Additionally, when
the expression is monitored from transfected plasmids, the con-
structs should be carefully analyzed for the absence of cryptic pro-
moters and potential splicing events [22,23]. To measure IRES
activity under conditions of cap-dependent inhibition, cells are
transfected with the IRES reporter plasmids and a plasmid express-
ing the L protease of aphthovirus or the 2A protease of enterovirus
[24,25]. Both 2A and L proteases induce the cleavage of eIF4G,
among other host factors, inhibiting cap-dependent translation
but allowing viral IRES-dependent translation. Alternative
approaches to analyze IRES activity rely on viral cDNA clones
within which parts of the genome can be modiﬁed. This approach
allows determining protein synthesis within the viral RNA context
[26], in addition to analyze potential effects of viral proteins and
untranslated regions on IRES activity [27].2. RNA-afﬁnity methods to study IRES-protein interactions
IRES function depends on the interaction with host factors
[17,20]. In turn, these factors interact within the cell with other pro-
teins, which can inﬂuence IRES activity by indirect interactions.
RNA-afﬁnity methods to isolate and identify RBPs are crucial in
RNA biology research. Identifying the interaction of proteins with
RNA, as well as with other proteins, has been critical for the under-
standingofnetworks controllinggeneexpression.Avarietyof assays
have been developed to capture RBPs bound to speciﬁc mRNA tar-
gets, and to determine the impact of RBPs on IRES-mediated transla-
tion using living cells, cell-free extracts or Xenopus oocytes [28–30].
RNA afﬁnity chromatography followed by mass spectrometry (MS)
analysis allows for a sensitive proﬁling of RNA-protein interactions.
Combined with other molecular biology methodologies, this tech-
nique can determine RBPs recognizing speciﬁc RNAs and may also
be used to study the signiﬁcance of these targets in infected cells.
Then, the inﬂuence of the candidate RBPs on the target RNA should
be evaluated by silencing, or ectopically overexpressing the protein
of interest. Further, the consequences of RBP manipulation can be
studied by assessing target RNA stability and translation efﬁcacy.
Several approaches, described below, have been developed to iden-
tify proteins interacting with IRESs.2.1. Identiﬁcation of IRES-binding proteins by RNA-afﬁnity followed by
mass spectrometry
Proteomic approaches are often applied to identify RNA part-
ners using afﬁnity chromatography followed by mass spectrome-
try. For this, the RNA of interest is synthesized in vitro with
convenient tags for which high afﬁnity ligands are available.
These can be either biotin label incorporated on the RNA or
sequences added to the 50 or 30 end of the RNA, avoiding disrupting
the functional RNA conformation. Illustrative examples are poly(A)
tails, streptavidin aptamers, tobramycin (Tob)-aptamers, a short
open reading frame and a streptomycin aptamer, hairpins recog-
nized by high afﬁnity ligand proteins (e.g. MS2), among other pos-
sibilities [31–34]. Additionally, RNA–protein interactions can be
performed in the presence of a large molar excess of cytoplasmicRNA (RNAc) or tRNA as a non-speciﬁc competitor, to eliminate
the background of unspeciﬁc binding proteins. This methodology
includes several steps, described below.
2.1.1. RNA synthesis and cytoplasmic RNA preparation
Plasmids expressing the RNA of interest with appropriate tags
(Fig. 1A) should be prepared in advance. Then, in vitro transcription
of the full-length or speciﬁc IRES domains is performed using T7
RNA polymerase (10–50 U) with linearized plasmid DNA (1–
3 lg), 40 mM Tris–HCl pH 7.9, 50 mM DTT, 0.5 mM rNTPs, during
1 h at 37 C [35]. Newly synthesized RNA is extracted with phe-
nol–chloroform, ethanol precipitated and resuspended in TE
(10 mM Tris–HCl pH 8, 1 mM EDTA). RNA integrity is examined
by denaturing gel electrophoresis.
Total RNAc is isolated from conﬂuent mammalian cells grown
in 10-cm dishes, washed twice with cold phosphate buffer saline
(PBS) and lysed in buffer C (50 mM Tris–HCl pH 7.8, 120 mM
NaCl, 0.5% NP40) [36]. Following elimination of cellular debris,
RNAc is extracted from cytosolic extract using TriPure isolation
reagent (Boehringer Mannheim). RNAc is ethanol precipitated,
resuspended in TE and then, the RNA concentration estimated from
the OD measured at 260 nm.
2.1.2. Preparation of S10 cellular extracts
For S10 cell extracts preparation BHK-21, HEK293 or HeLa cells
are grown in 10-cm dishes to 100% conﬂuence. Then, cells are
washed twice with cold PBS, scraped, and collected by centrifuga-
tion. The cellular pellet is resuspended in 1 volume of ice-cold
hypotonic buffer (10 mM HEPES-KOH pH 7.4, 10 mM KAc,
1.5 mM MgAc, 2.5 mM DTT) and homogenized by 30 strokes in a
1 ml glass Dounce on ice. The cellular debris is eliminated by cen-
trifugation at 5000g for 5 min at 4 C. The clear lysate is then spin
down at 10,000g for 5 min at 4 C, adjusting the supernatant to
3% glycerol [36]. To prepare cap-independent cell extracts, eIF4G
is proteolyzed by transfection of cells with a plasmid expressing
the L protease of FMDV 12–16 h before extract preparation.
Following elimination of cellular debris, the extract is further incu-
bated at room temperature for 5–10 min to allow total cleavage of
eIF4G by the L protease in the cell lysate. Monitoring of the pres-
ence of intact eIF4G in the S10 cell extracts as well as the extent
of eIF4G cleavage in L-transfected cell extracts is performed by
western blot assay [36]. Total protein concentration is measured
by the Bradford assay (Biorad).
2.1.3. Protein complexes identiﬁcation by RNA afﬁnity puriﬁcation
For constructs including a tract of adenines at the 30 end of the
RNA (Fig. 1A), transcripts (2.5 lg) are incubated with oligo-dT
magnetic beads (Life Technologies) (Fig. 1B) in binding buffer
(25 ll) (10 mM Tris–HCl pH 7.5, 100 mM KCl, 2 mM MgCl2) at
4 C for 30 min on a rotating wheel [32]. Unbound RNA is removed,
and the beads-RNA complexes are washed twice with binding buf-
fer. Then, beads-RNA complexes are incubated with S10 extracts
(100 lg) prepared from BHK-21, HEK293 or HeLa cells (Fig. 1C)
in the presence of a 100-fold molar excess of RNAc or tRNA as
non-speciﬁc competitors, at 4 C during 15 min. Unbound proteins
are removed by washing with binding buffer, followed by two
washes with 10 mM Tris–HCl pH 7.5, 100 mM KCl, 0.5 mM
MgCl2. A small aliquot of the polypeptides associated to the
RNA-beads are fractionated by SDS–PAGE in parallel to samples
processed with a control RNA (Fig. 1D), and visualized by silver
staining (Amersham). In parallel, the protein samples are pro-
cessed for mass spectrometry analysis [29].
Alternative methods to identify RBPs make use of biotinylated
RNAs [31] or streptavidin aptamer-tagged RNAs [33] (Fig. 1A),
allowing RNA binding to streptavidin-coated magnetic beads
(Fig. 1B). Subsequently, the beads-RNA complexes are incubated
Fig. 1. RNA afﬁnity puriﬁcation of proteins bound to viral IRESs. (A) Schematic representation of transcripts synthesized in vitro, corresponding to the entire RNA element or a
domain, poly(A) tail-tagged (AAA), biotin-labeled at the 50 end (yellow box), or aptamer-tagged at the 30 end (red hairpin). (B). Representative examples of RNA-pull down
assay. A blue rectangle depicts the RNA under study, grey circles depict magnetic beads coated with oligo-d(T)25 or streptavidin (Strep). Green balls depict the aptamer high-
afﬁnity ligand. (C) Protein binding to beads-RNA complexes and washing of the unspeciﬁc-bound factors, followed by elution of the afﬁnity-binding proteins. (D) SDS–PAGE
gel of proteins bound to the RNA. (E) Mass spectrometry analysis of the proteins interacting with viral RNA. MS/MS scan spectrum of a peptide resulting from trypsin
digestion.
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folding, the streptavidin aptamer sequence (50-CGACCAGAAUCAU
GCAAGUGCGUAAGAUAGUCGCGGGUCG-3) has high afﬁnity for
streptavidin. For biotinylated RNAs or constructs tagged with
streptavidin aptamers, Dynabeads M-280 Streptavidin (Life
Technologies) are used to capture RNA. Prior to incubate the beads
with RNA, the beads suspension is treated with ﬁve volumes of
washing buffer (5 mM Tris–HCl pH 7.5, 0.5 mM EDTA, 1 M NaCl)
5 min with gentle rocking at room temperature, followed by
2 min on the magnet to discard the supernatant. Next, beads are
cleaned of RNases and other contaminants by soaking once with
solution A (0.1 M NaOH, 0.05 M NaCl) and twice with solution B
(0.1 M NaCl). The clean beads pellet collected on the tube wall is
resuspended in solution B (100 ll). RNA binding is then carried
out in a ﬁnal volume of 500 ll of binding buffer (0.1 mM
HEPES-KOH pH 7.4, 6 mM MgCl2, 0.1 M NaCl) and RNA (20 pmol)during 30 min at room temperature rotating in a wheel. The
beads-RNA complexes are collected in the tube wall standing on
the magnet 3 min, and the supernatant is removed, followed by
three washes with binding buffer to eliminate unbound RNA
(Fig. 1B).2.1.4. Mass spectrometry identiﬁcation
The RNA afﬁnity-puriﬁcation samples are appropriate to be
analyzed by mass spectrometry (MS). Proteins bound to a control
RNA are analyzed in parallel to identify unspeciﬁc binding pro-
teins. For this, samples are applied onto a SDS–PAGE gel, stopping
the run to concentrate the proteome in the stacking/resolving gel
interface. Proteins are visualized by Coomassie blue staining,
excised, cut into small cubes, distained, and digested with
sequencing grade trypsin (Promega) [37]. The protein digest is ana-
lyzed by reverse phase-liquid chromatography (RP-LC)-MS/MS in
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LTQ-Orbitrap-Velos-Pro mass spectrometer (Thermo Scientiﬁc).
The peptides are concentrated and then eluted using a 90-min gra-
dient from 5 to 40% of 0.1% formic acid, 80% acetonitrile in water.
Electrospray ionization (ESI) is done using a Nano-bore emitters
Stainless Steel ID 30 lm (Proxeon) interface. The Orbitrap resolu-
tion is set at 30.000. The mass spectrometer is operated in the
selected MS/MS ion-monitoring mode (SMIM mode). The
LTQ-Orbitrap-Velos-Pro detector is programmed to perform a con-
tinuous sequential operation in the MS/MS mode on the doubly or
triply charged ions corresponding to the peptide/s selected previ-
ously from the theoretical prediction. The MS/MS peptide spectra
is analyzed by assigning the fragments to the candidate sequence
after calculation the series of theoretical fragmentations, according
to the nomenclature of the series [38].
2.2. Functional analysis of the identiﬁed proteins on gene expression
Once a protein interacting with the RNA of interest is identi-
ﬁed, several strategies can be used to study whether, or not, this
factor has a role on the function of the analyzed RNA. The can-
didate protein can be either overexpressed or depleted, using
siRNAs or shRNAs. Next, a tagged version of the protein can be
expressed to reconstitute its function in depleted cells, for
instance, measuring the impact of the tagged protein on the
expression of reporter genes transcribed from a cotransfected
dicistronic plasmid [39]. Alternatively, transfection of mono-
cistronic constructs or viral RNAs can provide information about
the level of expression of speciﬁc proteins. siRNAs targeting the
mRNA encoding the protein of interest can be designed from
Dharmacon (www.dharmacon.gelifesciences.com/design-center/).
For siRNA silencing, HEK293 cells grown in 3.5 cm dishes to
70% conﬂuent are transfected with 20–100 nM siRNA (depending
upon the effectiveness of the siRNA) using lipofectamine 2000
(Life Technologies). Cell lysates are prepared 24, 48 or 56 h later
in 100 ll of lysis buffer C, and the protein concentration in the
lysate measured by Bradford assay. The efﬁciency of interference
is veriﬁed by western blot (WB). Equal amounts of total protein
are resolved in SDS–gels, and then transferred to PVDF mem-
branes (Biorad). Membranes are probed with appropriate pri-
mary antibodies; a-tubulin (Sigma) is often used as loading
control. Following incubation with the convenient secondary
HRP-conjugated antibody (Thermo Scientiﬁc), proteins are
revealed by ECL detection (Millipore).
2.3. RNA–protein interaction assays
The methodologies developed to study the type of interaction
between RNA and proteins rely on the availability of appropriate
tools, typically, (i) RNA synthesized in vitro which can be unla-
beled, radiolabeled or ﬂuorescent-labeled, (ii) the puriﬁed protein
which is often tagged for convenient immunodetection, and (iii)
a cellular extract in which the protein can be depleted or overex-
pressed. Using appropriate controls, these methodologies allow
visualizing either the RNA or the protein bound to it, and to distin-
guish speciﬁc interactions from background binding.
2.3.1. RNA synthesis
In vitro transcription of the full-length or speciﬁc IRES domains
is usually performed using T7 RNA polymerase with linearized
DNA. IRES transcripts are uniformly labeled using a32P-CTP
(500 Ci/mmol). Then, template DNA is digested with DNase RQ1
(Promega) and the unincorporated isotope excluded using Illustra
Microspin G25 columns (GE Healthcare). Labeled RNA is ethanol
precipitated and resuspended in TE to a concentration of0.04 pmol/ll. RNA integrity is examined in 6% acrylamide 7 M urea
denaturing gel electrophoresis [40].2.3.2. Expression and puriﬁcation of proteins from bacteria or
mammalian cells
Escherichia coli BL21 transformed with bacterial expression
plasmids are usually grown at 37 C and then induced with iso-
propyl b-D-1-thiogalactopyranoside (IPTG) 0.5 mM for about 2 h.
Time of induction and growth temperature needs to be optimized
for each protein. In cases where the protein expression is low or
even undetectable, growing the cells at lower temperatures, and/or
use longer induction time may help. Bacterial lysates are prepared
in binding buffer (20 mM NaH2PO4, 500 mM NaCl, 20 mM
Imidazol). Cell debris is pelleted at 16,000  g, 30 min at 4 C twice.
The clear lysate is then loaded on His-GraviTrap columns (GE
Healthcare), washed at least twice, and the recombinant protein
eluted using 500 mM Imidazol. Proteins are dialyzed against phos-
phate buffer pH 6.8, 1 mM DL-dithiothreitol (DTT), and stored in
small aliquots at 20 C in 50% glycerol until used.
For puriﬁcation of proteins expressed in mammalian cells it is
convenient to use tagged proteins. For instance, the vector
pcDNA3/Xpress allows expression of amino terminal HIS-Xpress
tagged protein [41]. Proteins can be visualized in cell lysates by
WB, and later puriﬁed by afﬁnity procedures [32].2.3.3. RNA–protein photocrosslinking using puriﬁed proteins
Uniformly radiolabeled transcripts (0.04 pmol, 5  105 cpm)
are incubated with puriﬁed proteins (50–200 ng), depending on
the factor analyzed [39]. Binding reactions are carried out in
10 mM HEPES-KOH pH 7.4, 35 mM KCl, 2.75 mM MgCl2, 10% glyc-
erol, 0.05% NP40, 0.5 mMDTT, 1 lg/ll yeast tRNA, in a ﬁnal volume
of 16 ll. Reactions are incubated 15–20 min at room temperature
and exposed to UV light (254 nm, Stratalinker 1800, Stratagene)
3  104 lJ at a distance of 10 cm from the lamp. In RNA–protein
competition assays, unlabeled RNA is added to the binding mixture
prior to the labeled transcript (0.025 pmol) and incubated 3 min at
room temperature. RNA is then digested by extensive treatment
with 0.3 lg/ll of RNase A during 40 min at 37 C, to eliminate
unbound probe and most of the unprotected RNA, except for the
few nucleotides covalently linked to proteins after UV irradiation.
Loading buffer is added to the samples, boiled for 2 min, and
resolved by SDS–PAGE. Subsequently, the 32P-labeled proteins
are detected by autoradiography of the dried gels. Intensity of
the crosslinked products is measured in a Phosphorimager [36].
This method is also suitable to analyze direct interactions
between proteins present in S10 cell extracts and the labeled
RNA when coupled to immunoprecipitation of the pho-
tocrosslinked complexes with speciﬁc antibodies, as illustrated
for eIFs and ITAFs interacting with viral IRES [32,36,42–44].2.3.4. RNA gel-shift assays
RNA–protein binding reactions are carried out for 20 min at 4 C
in 10 ll of 40 mM Tris–HCl pH 7.5, 250 mM NaCl, 0.1% (w/v)
2-Mercaptoethanol (b-ME). Increasing amounts of protein are
incubated with a ﬁxed concentration of 32P-labeled RNA (2 nM).
Electrophoresis is performed in non-denaturing 8.0% (29:1) poly-
acrylamide gels, run for 4 h in TBE buffer (90 mM Tris–HCl,
64.6 mM boric acid, 2.5 mM EDTA pH 8.4) at 100 V at 4 C. Dried
gels are exposed to a PhosphorImager screen. The intensity of the
retarded complex is normalized relative to the free probe, run in
parallel. The values obtained with increasing amounts of protein
allow determining the RNA binding afﬁnity to the protein of inter-
est [39,45].
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An alternative method to analyze RNA protein interaction takes
advantage of the use of HIS-tagged proteins. For this,
Ni-NTA/HIS-protein complexes are assembled by incubating
Ni-NTA agarose resin (25 ll) (Qiagen), pre-washed four times with
cold BBH buffer (10 mM HEPES-KOH pH 7.4, 100 mM NaCl, 2.5 mM
MgCl2, 0.01% NP-40), with the polypeptide of interest (0.7 pmol) in
100 ll of BBH buffer during 4 h at 4 C in a rotating wheel.
Unbound proteins are removed by washing three times with cold
BBH buffer. 32P-labeled RNA (80 fmol) is added to each
protein-beads complex and incubated in cold BBH buffer in the
presence of RNAc (300-fold excess) 2 h at 4 C in a rotating wheel.
Unbound RNA is removed by washing ﬁve times with cold BBH
buffer. Bound RNAs are extracted with phenol–chloroform, ethanol
precipitated, fractionated by 6% acrylamide 7 M urea denaturing
gel electrophoresis, and visualized by autoradiography [41].
2.4. Protein complexes puriﬁcation by TAP (tandem afﬁnity
puriﬁcation)
ITAFs interact with secondary partners, which could inﬂuence
IRES-mediated translation. In this regard, proteomic analysis is a
powerful tool to study protein–protein interactions in living cells
using immuno-afﬁnity chromatography followed by mass spec-
trometry. For this, the protein of interest is fused in-frame with
an N- or C-terminal tag using the plasmids pcDNA3-NTAP and
pcDNA3-CTAP [46]. The TAP cassette includes a distal tag derived
from the IgG binding moiety of Staphylococcus aureus protein A
(Protein A) and a proximal tag that is a calmodulin-binding pep-
tide, both separated by a tobacco etch virus (TEV) protease cleav-
age site (Fig. 2A). To isolate the protein complexes present in
mammalian cells associated to an ITAF we followed the strategy
developed for yeast [47,48], including modiﬁcations in the protocol
to optimize puriﬁcation of cytoplasmic proteins. Optional protocol
variations (Fig. 2B), such as RNase treatment, allow the analysis of
RNA-mediated interactions.
HEK293 cells (grown in 4  150 mm plates) are transfected
with the TAP-fusion plasmids and harvested 24–48 hpt, depending
on the optimal expression time of the TAP-tagged proteins. Cell
monolayers are washed with ice cold PBS and lysed in buffer LyB
(10% glycerol, 50 mM Tris–HCl pH 7.5, 150 mM NaCl, 2 mM
EDTA, 0.1% NP40, 2 mM DTT, Complete mini (Roche)). After spin-
ning down for 10 min at 14,000  g at 4 C, the supernatant is
transferred to Econo-Pac column (Biorad) loaded with
IgG-Sepharose beads (GE Healthcare) (400 ll), prewashed ten
times with 1 ml of LyB, and incubated at 4 C overnight with gentle
rocking. Proteins are eluted by gravity ﬂow, washing the beads ﬁve
times with 20 ml of LyB and ﬁve times with 5 ml of TEV buffer
(10 mM Tris–HCl pH 8, 150 mM NaCl, 0.5 mM EDTA, 0.1% NP40,
1 mM DTT). Next, TEV protease treatment is carried out adding
1.5 ml of TEV buffer and TEV protease (150 U) (Life Technologies)
to the column, incubating 2 h at 4 C. The protein complexes are
eluted by gravity ﬂow. To eliminate the factors mediated by RNA
bridges, the elution products are treated with RNase A
(75 lg/1.5 ml) during 30 min at room temperature.
Calmodulin-agarose resin (Agilent Technologies) (400 ll of
bead suspension loaded into an Econo-Pac column) is equilibrated
by washing ten times with 1 ml of Calmodulin Binding Buffer (CBB)
(10 mM Tris–HCl pH 8, 150 mM NaCl, 10 mM b-ME, 0.1% NP40,
1 mMMgOAc, 1 mM Imidazole, 2 mM CaCl2, 1 mM PMSF). The elu-
tion products are mixed with 4 ml of CBB and 4 ll of CaCl2 1 M,
transferred to the column, and rocked at 4 C during 1.5 h.
Elution is done by gravity ﬂow, washing the beads ﬁve times with
20 ml of CBB. Bound proteins are recovered with elution buffer
(10 mM Tris–HCl pH 8, 150 mM NaCl, 10 mM b-ME, 0.1% NP40,
1 mM MgOAc, 1 mM Imidazole, 2 mM EGTA, 1 mM PMSF) in5  200 ll fractions, with 10 min interval between elutions.
Proteins are precipitated adding trichloroacetic acid (TCA) to a ﬁnal
concentration of 10%, incubating the sample at 4 C overnight.
Samples are pelleted at 14,000g for 15 min at 4 C, removing
the supernatant. To ensure TCA elimination, the pellet is washed
three times with 1 ml of acetone and ﬁnally dissolved in loading
buffer. A small aliquot is analyzed on silver stained SDS–PAGE gels
to verify the puriﬁcation of proteins associated to the TAP-ITAF
protein (Fig. 2C).
The samples obtained by TAP-puriﬁcation are optimal to be
analyzed by Mass Spectrometry (MS), described in Section 2.1.4.
Negative controls (TAP-puriﬁcation of cell extracts expressing the
empty TAP-tag vector) are conducted in parallel to discard back-
ground contaminants.
2.5. GST-pull down assay
The MS/MS technology often identiﬁes a large amount of factors
copurifying with the TAP-tagged protein of interest, irrespectively
of whether the binding is direct or indirect. Pull down assays can
be next used to analyze the interaction [45]. For this, the factors
are puriﬁed as glutathione S-transferase (GST)-fusions [49], and
the ITAF under study is puriﬁed as a HIS-tag fusion.
2.5.1. GST-fusion protein puriﬁcation
E. coli BL21 transformed with the GST-fusion plasmids (pGEX)
(GE Healthcare) grown at 37 C are induced with 0.5 mM IPTG dur-
ing the appropriate time (1–6 h). The bacterial pellet is resus-
pended in 10 ml of ice cold PBS, 2 mM DTT. The cell suspension
transferred to a clean centrifuge tube, adding one volume of
0.1 mm glass beads (Scientiﬁc Industries). Cells are then lysed by
8 cycles of vortexing 30 s with intervals of 1 min on ice. Cell debris
and glass beads are pelleted at 16,000g, 30 min at 4 C. The super-
natant is transferred to a clean 15 ml tube, mixed with 150 ll of
glutathione Sepharose resin (GE Healthcare) equilibrated with
PBS, 2 mM DTT, and rotated on a wheel at 4 C for 2 h. Following
centrifugation at 3000g 2 min at 4 C, the supernatant is dis-
carded, the beads are resuspended in 1 ml of PBS, 2 mM DTT, and
transferred to a 1.5 ml tube. The resin is washed three times with
1 ml of PBS, 2 mM DTT, rotating 5 min at 4 C and pelleted at
3000g, 2 min at 4 C. Finally, the recombinant GST-protein bound
to the beads is resuspended in 30 ll of PBS, 2 mM DTT, 100 ll of
glycerol and stored at 20 C.
2.5.2. Protein–protein binding assay
Binding reactions are performed in binding buffer (BB) (50 mM
HEPES-KOH pH 7.4, 100 mM NaCl, 2 mM DTT, 2 mM MgCl2, 0.5%
Igepal CA-630, 10% glycerol) using 4 lg of the GST-protein bound
to the glutathione resin, an appropriate amount of the puriﬁed
HIS-ITAF (100–1000 ng) and ﬁve volumes of BB, at 4 C for 2 h
rotating in a wheel. Then, the samples are pelleted at 3000g,
2 min at 4 C, removing the supernatant. The beads pellet is
washed three times with ﬁve volumes of BB rotating for 5 min at
4 C, centrifuging at 3000g 2 min at 4 C. Beads are then boiled
in loading buffer for SDS–PAGE analysis and WB analysis using
anti-GST to detect the GST-protein, and anti-HIS to detect the
ITAF of interest [45].3. RNA structural analysis of viral IRESs
3.1. Analysis of sequence covariation and identiﬁcation of conserved
motifs
Evolutionary conserved motifs determine the RNA structure
organization of viral IRESs [50]. Conserved sequences essential
Fig. 2. (A) Schematic representation of the tandem-afﬁnity puriﬁcation (TAP)-tagged fusion protein. CBP stands for calmodulin binding protein, TEV for tobacco etch virus
protease, ProtA for S. aureus protein A. (B). Overview of TAP-puriﬁcation procedure. The fusion protein is colored as in A. The basic puriﬁcation steps include protein A-IgG
resin afﬁnity puriﬁcation, TEV protease cleavage, optional RNase A digestion if RNA-mediated interactions are disrupted, calmodulin-Ca2+ resin binding and ﬁnally EGTA
elution. (C) Representative example of TAG-puriﬁed proteins. A silver stained SDS–PAGE gel loaded with proteins bound to the vector (control TAP) and TAP-ITAF puriﬁed
proteins. Mw depicts molecular weight markers. An arrow depicts the TAP-tagged ITAF.
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retrieved from GenBank using Blast (http://blast.ncbi.nlm.nih.-
gov/Blast.cgi). Duplicates and incomplete sequences must be
removed and each sequence is given a unique identiﬁer.
FASTA-formatted sequences are aligned using CLUSTALW
(http://www-ebi.ac.uk/Tools/clustaw2/index.html). RNA sec-
ondary structure features inferred from mutational analysis
and RNA probing data are used to manually adjust the
alignment.
Sequence covariation, indicative of base pairs within the RNA
secondary structure, can be identiﬁed by mutual information
(MI) analysis. This procedure computes the probability of ﬁnding
the nucleotide X in position i the probability of ﬁnding the nucleo-
tide Y in position j, and the joint probability of simultaneously ﬁnd-
ing a particular combination of nucleotides X,Y in positions i,j,respectively. MI is calculated for all possible pairs of variable col-
umns in the multiple alignment [51]. Vertical shufﬂing of all the
columns identiﬁes pairs with MI value signiﬁcantly different from
random expectation. The distribution of the MI values in random-
ized alignments is used to calculate the z-scores. Variable pairs are
classiﬁed as covariant, if z-score > 2.96, or independent, otherwise.
Each variable pair is further classiﬁed as conservative or
non-conservative, if the frequency of nt substitutions that pre-
served the canonical base pairing is higher or lower than 50%,
respectively.
Additionally, consensus sequences can be visualized by a
sequence logo generated from the alignment of the IRES sequences.
Nucleotide positions are represented as stacks, in which the overall
height of each stack indicates the sequence conservation at that
position (measured in bits), whereas the height of symbols within
R. Francisco-Velilla et al. /Methods 91 (2015) 3–12 9the stack reﬂects the relative frequency of the corresponding
nucleic acid at that position (http://weblogo.berkeley.edu).
3.2. Selective 20-hydroxyl acylation analyzed by primer extension
(SHAPE) RNA structure analysis
Different approaches are available to determine the RNA
three-dimensional structure, including X-ray, NMR, SAXS, or
cryo-EM. However, these methodologies are often hard to imple-
ment due to the difﬁculties to obtain crystals (X-ray), the limits
of the size of the RNA to be studied (NMR), or the problems to pre-
pare stable ribonucleoprotein complexes (cryo-EM). Alternatively,
local nucleotide conformation can be analyzed using other
approaches in which RNA is chemically or enzymatically treated.
SHAPE-probing is one of the recent advances in structural analysis
of RNA molecules. In this technique, RNA is treated with a
hydroxyl-selective electrophilic reagent forming 20-O-adducts with
unconstrained nucleotides that can be later identiﬁed by primer
extension reaction. This methodology offers the advantage of
attacking nucleotides irrespectively of their identity, and with
low inﬂuence of solvent accessibility [52]. Analysis of long RNAs
in solution by SHAPE provides information on the entire element
and the ﬂanking regions, which may induce a local reorganization
of the RNA element. Furthermore, it also allows one to measure the
impact of RBPs and other RNA ligands on RNA structure.
This methodology includes several steps, described below.
3.2.1. RNA treatment
RNA (2 pmol) is treated with N-methylisatoic anhydride (NMIA)
(Life Technologies) as SHAPE reagent [52]. Other SHAPE reagents
[benzoyl cyanide (BzCN), 1-methyl-7-nitroisatoic anhydride
(1M7), 1-methyl-6-nitroisatoic anhydride (1M6), isatoic anhydride
(IA)] with different features can be selected depending on the aim
of the study [53–55]. Prior to NMIA treatment, in vitro synthesized
RNA is renatured by heating at 95 C for 2 min, snap cooling on ice
for 2 min, and subsequently incubated in a ﬁnal volume of 18 ll of
folding mix (100 mM HEPES-KOH pH 8.0, 0.5 mM MgCl2, 100 mM
NaCl) for 20 min at 37 C. The concentration of MgCl2 can be varied
between 0 to 6 mM to study the effect of ionic strength on RNA
folding [56]. Then, RNA are incubated with dimethyl sulfoxide
(DMSO) (untreated RNA) or 6.5 mM NMIA (for molecules about
1000–1300 nts long; shorter or longer RNAs may need to adjust
the concentration of the reagent) for 45 min at 37 C, precipitated
and resuspended in 10 ll of 0.5X TE.
3.2.2. Primer extension
For primer extension using ﬂuorescently labeled primers, trea-
ted and untreated RNAs (2 pmol) are incubated with the antisense
50-end ﬂuorescently-labeled primer (2 pmol) (complementary to a
sequence of the RNA target located 50–80 nt downstream of the
sequence of interest) at 65 C for 5 min, 35 C for 5 min and then,
chilled on ice for 2 min. Primer extension reactions are conducted
in a ﬁnal volume of 16 ll, containing reverse transcriptase (RT)
buffer (50 mM Tris–HCl pH 8.3, 3 mM MgCl2, 75 mM KCl, 8 mM
DTT) and 1 lM each dNTP. The mix is heated at 52 C for 1 min
prior to addition of 100 U of Superscript III RT (Life Technologies)
and incubated at 52 C for 30 min. The enzyme is inactivated heat-
ing at 70 C for 15 min. A sequencing ladder is generated using the
same transcript (1 pmol), 0.1 mM ddCTP and 0.5 mM each dNTP.
NED ﬂuorophore (Applied Biosystems) is used for both
NMIA-treated and untreated RNAs, while FAM ﬂuorophore is used
for the sequencing ladder. Primer extension products are resolved
by capillary electrophoresis. A single run allows reading at least
500 nts [56].
For primer extension reactions using radiolabeled primers [51],
equal amounts of NMIA-treated and untreated RNAs (0.5 pmol) areincubated with antisense 50-end 32P-labeled primers (2 pmol)
(each primer allows the analysis of around 125 nt) following the
protocol described above. After RT reaction is completed, the
RNA template is hydrolyzed in 20 ll of 50 mM Tris–HCl, pH 7.5,
7.5 mM EDTA, 0.5% SDS adding 3.5 ll of 3 M KOH, incubating for
3 min at 95 C followed by 1 h at 37 C. Hydrolysis is stopped add-
ing 6 ll of 3 M acetic acid. RT-products are precipitated with 2 lg
of glycogen carrier and resuspended in 10 ll of water supple-
mented with denaturing loading buffer (90% formamide, 1 mM
EDTA pH 8, 0.1% xylencianol, 0.1% bromophenol). Following denat-
uration during 3 min at 95 C, the samples are loaded in 6% acry-
lamide, 7 M urea gels, in parallel to a sequence ladder prepared
with the same labeled primer [56]. The extension products are
visualized after autoradiography of the dried gels for about 12 h
with intensifying screen. In all cases, formation of full-length pro-
duct at the top of the gel must be veriﬁed.3.2.3. SHAPE data analysis
SHAPE electropherograms obtained by capillary electrophoresis
are analyzed using QuSHAPE software with default parameters
[57]. The process includes four steps: (1) preprocessing of traces,
(2) signal alignment (Fig. 3A), (3) sequence alignment, and (4) reac-
tivity estimation by Gaussian peak integration (Fig. 3B). The reac-
tivity values obtained for the untreated RNA (NMIA-) are
subtracted from the NMIA-treated samples to obtain the net reac-
tivity as a function of the nucleotide position. Reactivity data from
at least three independent assays are used to calculate the mean
(±SD) SHAPE reactivity. Quantitative SHAPE reactivity for individ-
ual data sets are normalized to a scale spanning 0 to 2 (Fig. 3C),
in which 0 indicates an unreactive nucleotide and the average
intensity at highly reactive nts is set to 1.0 [56].
The intensities of RT-stops obtained using radiolabeled primers
and conventional denaturing gel electrophoresis [35,58] are quan-
tiﬁed by densitometry using Quantity One software (Bio-Rad). The
reactivity values obtained for the untreated RNA (NMIA-) are sub-
tracted from the NMIA-treated samples. Quantitative SHAPE reac-
tivity for individual data sets are normalized to a scale spanning 0
to 2, in which 0 indicates unreactive nucleotides and the average
intensity at highly reactive nucleotides is set to 1.0. The normaliza-
tion factor for each dataset is determined by excluding the
most-reactive 2% of peak intensities, followed by calculating the
average for the next 8% of peak intensities. All reactivity values
are normalized to this average value to generate the corresponding
SHAPE reactivity proﬁles [52].3.2.4. RNA structure modeling
Secondary RNA structure prediction accuracy can be increased
incorporating SHAPE reactivity values (Fig. 3D) as constraints in
RNA structure software [59]. SHAPE reactivity data is imposed as
a pseudo-free energy change constraint together with nearest
neighbor thermodynamic parameters using 0.8 kcal/mol and 2.6
for the intercept (b) and slope (m), respectively, as recommended
for large RNAs in RNA structure predictions [60]. The predicted
structure corresponding to the lowest minimal free energy (MFE)
energy is used to depict the RNA structure model. Secondary
RNA structure is visualized with VARNA [61].
Three-dimensional RNA structure models are predicted using
MC-Fold MC-Sym pipeline (www.major.iris.ca/MC-Pipeline).
SHAPE reactivity can be incorporated as constraint masks in
MC-Fold to obtain the secondary structure in bracket format fol-
lowed by MC-Sym generator to produce the PDB RNA structure.
RNA structure is visualized using Swiss-PdbViewer. The ﬁrst PDB
structure obtained with the MC-Sym generator using the most
stable energy RNA structure according to MC-Fold is used to depict
the RNA model.
Fig. 3. SHAPE RNA structure analysis resolved by capillary electrophoresis. (A) Processed electropherograms showing ﬂuorescence intensity versus nt position after QuSHAPE
preprocessing and signal alignment steps. The NMIA-treated and untreated reactions are shown in red and blue, respectively. RNA was renatured in folding buffer containing
6 mM MgCl2. ddC sequence ladders resolved in parallel to NMIA-treated or untreated reactions are shown in green and pink, respectively. (B) Integrated peak areas for the
NMIA-treated (red) and untreated (blue) samples after the reactivity estimation step. (C) Normalized SHAPE reactivity as a function of nucleotide position (290–462).
Reactivity is colored according to the scale shown at the top. (D) RNA secondary structure model predicted by RNA structure imposing SHAPE reactivity values shown in (C) as
constraints.
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SHAPE chemistry is amenable to detect conformational changes
in RNA structure occurring in ribonucleoprotein complexes by
comparison to the pattern of reactivity of the free RNA. For this, fol-
lowing RNA denaturation and folding, RNA–protein (or RNA-ligand
such as a small molecule or another RNA molecule) complexes are
assembled for 10 min at room temperature in high Mg2+ folding
buffer (100 mM HEPES-KOH pH 8.0, 6 mM MgCl2, 100 mM NaCl)
or low Mg2+ folding buffer (100 mM HEPES-KOH pH 8.0, 0.5 mM
MgCl2, 100 mM NaCl) in the presence of increasing concentrations
of the protein or the RNA ligand of interest [56,58,62]. Competition
between RBPs can be analyzed using a similar procedure [41].
Then, free RNA and protein–RNA complexes are treated with
NMIA and analyzed by primer extension analysis, as described in
Section 3.2.1.
To quantify the effect on nucleotide ﬂexibility induced by differ-
ent folding conditions or ligand binding using an unbiased
approach, difference proﬁles are calculated by subtracting the
reactivity values obtained for one condition from the reference.
Increased reactivity or protected residues are reported as positive
and negative values, respectively. Absolute differences in SHAPE
reactivity P0.3 arbitrary units and p-values < 0.05 obtained by
the unpaired two-tail Student´s t-test are taken to be statistically
signiﬁcant [55]. RNA–protein footprint can also be studied by
dimethyl sulfate (DMS) treatment (see below).3.4. RNA structure analysis by DMS modiﬁcation
Prior to the development of SHAPE chemistry, chemical and
enzymatic probing were used to study the RNA secondarystructure of viral IRESs [63–65]. DMS modiﬁes unpaired A, C and
G bases; however, only modiﬁed A and C bases halt reverse tran-
scription reaction at the base preceding the methylated residue
[66]. Occasionally, pausing of the RT reaction before a G base is
observed. Monitoring of changes in the RNA folding dependent
on divalent cations is ensured by comparison of the pattern of
DMS attack in native (N) versus denaturing (D) conditions. This
procedure detects the appearance of residues protected from
methylation in native RNA, which may be indicative of their
involvement in the formation of tertiary contacts and stacking of
purines in helices [67].3.4.1. DMS treatment of RNA in vitro
RNA (1 pmol) is incubated in 20 ll of buffer N (50 mM sodium
cacodylate pH 7.5, 300 mM KCl, 10 mM MgCl2) in the presence of
1 ll of DMS (Fluka) freshly diluted 1:5 in ethanol, 15 min at
20 C. For RNA treatment under denaturing conditions, RNA dis-
solved in RNase-free water is ﬁrst denatured during 3 min at
95 C, cool down in ice, and adjusted to 20 ll of buffer D (50 mM
cacodylate pH 7.5, 1 mM EDTA) prior to addition of 1 ll of DMS
and incubation at 20 C 15 min. The methylated RNA is
ethanol-precipitated using 2 lg of glycogen as carrier and resus-
pended in RNase free water, followed of primer extension analysis
[40,63].3.4.2. In vivo DMS footprint
In vivo footprint takes advantage of reagents that are permeable
to the cellular membrane. DMS recognizes RNA and DNA mole-
cules in a structure-dependent manner, providing information
about the accessibility of individual residues in vivo. For DMS treat-
ment, cells (about 107) are washed in cold PBS 20 hpt, scraped in
R. Francisco-Velilla et al. /Methods 91 (2015) 3–12 11PBS (2 ml), pelleted and resuspended in PBS (100 ll). Then, DMS
(1 ll) is added to the cell suspension, incubated 2 min at room
temperature with gentle shaking [68]. Optimal DMS concentration
and time of cell treatment is determined using a 10-fold DMS con-
centration range in parallel wells. The reaction is stopped by addi-
tion of b-ME (10 ll), prior to increase the volume to 200 ll with
PBS and to extract total RNA using Trizol reagent (Life
Technologies). As a control of untreated cells, an aliquot of trans-
fected cells is processed in the same way except that no DMS is
added.
Sites of DMS modiﬁcation are identiﬁed by inhibition of RT
elongation in triplicate experiments using total RNA prepared from
transfected cells [68]. The optimal amount of total RNA for primer
extension analysis is determined using different RNA concentra-
tions prepared from transfected cells. Total RNA from
mock-transfected cells is used as negative control. For primer
extension, total RNA (about 30 lg) is denatured 3 min at 95 C.
Primer extension reactions are performed under the same condi-
tions than RNA subjected to in vitro probing (see Section 3.2.2).4. Concluding remarks
Here we have described distinct approaches for studying viral
IRES function, IRES-protein interaction and structural organization
using in vitro and in vivo methodologies. It is worth mentioning
that complementary in vitro approaches, such as reconstitution of
translation competent complexes using puriﬁed factors, are pow-
erful in elucidating the mechanism used by IRESs to recruit the
translation machinery. However, analyzing the factors that impact
on IRES function in vivo is critical to understand the mode of action
of these regulatory elements within the cell in response to different
environmental factors. Transfection of dicistronic reporter con-
structs and viral RNA replicons in tissue culture cells has been
widely used for testing IRES function. In addition, characterization
of RNA-binding proteins modulating IRES activity is crucial to get a
comprehensive understanding of viral IRESs, not only due to the
recognition of speciﬁc RNA sequence motifs or sensing conforma-
tional changes of the IRES RNA structure, but also by reorganiza-
tion of the network of proteins within the cellular compartments.
Moreover, analysis of the RNA conformation in response to envi-
ronmental changes, ligand binding and ribonucleoprotein com-
plexes assembly is essential to fully understand the molecular
basis of IRESs function. Currently, implementation of in vivo RNA
probing methodologies with next-generation sequencing
(SHAPE-seq or DMS-seq) has opened new avenues to determine
the structural organization of functional RNAs within the cellular
environment. Interestingly, in vivo RNA structurome studies pro-
vide information concerning a large variety of cellular processes
mediated by RNA molecules, such as alternative splicing, alterna-
tive polyadenylation, energy-dependent unfolding of mRNA, and
translation control. Furthermore, the IRES strategy developed by
RNA viruses for protein synthesis is used by a subset of host
mRNAs during cellular stress and virus infection when
cap-dependent translation is inhibited. Thus, understanding the
mechanism of action of the different types of viral IRESs may help
to determine the mechanism by which cellular mRNAs are
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